公开(公告)号：US20240024338A1

公开(公告)日：2024-01-25

申请号：US18334738

申请日：2023-06-14

Applicant: AbbVie Inc.

Inventor： Benoit Cardinal-David ,  Vincent S. Chan ,  Kassibla E. Dempah ,  Brian P. Enright ,  Rodger F. Henry ,  Raimundo Ho ,  Ye Huang ,  Alexander D. Huters ,  Russell C. Klix ,  Scott W. Krabbe ,  Philip R. Kym ,  Yanbin Lao. ,  Xiaochun Lou ,  Sean Mackey ,  Mark A. Matulenko ,  Peter T. Mayer ,  Christopher P. Miller ,  James Stambuli ,  Valentino J. Stella ,  Eric A. Voight ,  Zhi Wang ,  Geoff G. Zhang

IPC: A61K31/661 ,  A61K9/00 ,  A61K9/14 ,  A61K45/06 ,  A61K9/08 ,  C07F9/12

CPC classification number: A61K31/661 ,  A61K9/0019 ,  A61K9/14 ,  A61K45/06 ,  A61K9/08 ,  C07F9/12

Abstract: The present disclosure relates to (a) carbidopa prodrugs, (b) pharmaceutical combinations and compositions comprising a carbidopa prodrug and/or an L-dopa prodrug, and (c) methods of treating Parkinson's disease and associated conditions comprising administering a carbidopa prodrug and an L-dopa prodrug to a subject with Parkinson's disease.